Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Buy
54
LOVE.V Quote, Financials, Valuation and Earnings
Last price:
$1.71
Seasonality move
:
32.75%
Day range:
$1.66 - $1.70
52-week range:
$0.69 - $1.99
Dividend yield:
0%
P/E ratio:
11.90x
P/S ratio:
1.45x
P/B ratio:
1.57x
Volume:
28.4K
Avg. volume:
52.6K
1-year change:
116.67%
Market cap:
$160.5M
Revenue:
$107.2M
EPS (TTM):
$0.14
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
LOVE.V
Cannara Biotech, Inc.
|
-- | -- | -- | -- | $3.50 |
|
COOL.CX
Core One Labs, Inc.
|
-- | -- | -- | -- | -- |
|
CURE.X.CX
Biocure Technology
|
-- | -- | -- | -- | -- |
|
HEAL.CX
|
-- | -- | -- | -- | -- |
|
NSHS.CX
NanoSphere Health Sciences, Inc.
|
-- | -- | -- | -- | -- |
|
XLY.TO
Auxly Cannabis Group, Inc.
|
$35.9M | -- | 18.12% | -- | $0.2500 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
LOVE.V
Cannara Biotech, Inc.
|
$1.69 | $3.50 | $160.5M | 11.90x | $0.00 | 0% | 1.45x |
|
COOL.CX
Core One Labs, Inc.
|
$0.15 | -- | $6.8M | -- | $0.00 | 0% | 32.71x |
|
CURE.X.CX
Biocure Technology
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
HEAL.CX
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
NSHS.CX
NanoSphere Health Sciences, Inc.
|
$0.0200 | -- | $205.5K | 0.52x | $0.00 | 0% | -- |
|
XLY.TO
Auxly Cannabis Group, Inc.
|
$0.1400 | $0.2500 | $188.8M | 4.59x | $0.00 | 0% | 1.40x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
LOVE.V
Cannara Biotech, Inc.
|
28.92% | 0.801 | 25.26% | 0.83x |
|
COOL.CX
Core One Labs, Inc.
|
-- | 0.000 | -- | -- |
|
CURE.X.CX
Biocure Technology
|
-- | 0.000 | -- | -- |
|
HEAL.CX
|
-- | 0.000 | -- | -- |
|
NSHS.CX
NanoSphere Health Sciences, Inc.
|
-3.43% | 1.456 | 20.53% | 0.00x |
|
XLY.TO
Auxly Cannabis Group, Inc.
|
27.67% | -1.082 | 33.75% | 1.03x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
LOVE.V
Cannara Biotech, Inc.
|
$3.4M | -$3.1M | 9.23% | 13.81% | -10.91% | $467.5K |
|
COOL.CX
Core One Labs, Inc.
|
-- | -- | -- | -- | -- | -- |
|
CURE.X.CX
Biocure Technology
|
-- | -- | -- | -- | -- | -- |
|
HEAL.CX
|
-- | -- | -- | -- | -- | -- |
|
NSHS.CX
NanoSphere Health Sciences, Inc.
|
-- | -$72.1K | -- | -- | -- | -$92.1K |
|
XLY.TO
Auxly Cannabis Group, Inc.
|
$8.8M | -$4.1M | 22.71% | 34.07% | -10.27% | $8.3M |
Cannara Biotech, Inc. vs. Competitors
-
Which has Higher Returns LOVE.V or COOL.CX?
Core One Labs, Inc. has a net margin of 11.7% compared to Cannara Biotech, Inc.'s net margin of --. Cannara Biotech, Inc.'s return on equity of 13.81% beat Core One Labs, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital LOVE.VCannara Biotech, Inc.12.11% $0.04 $143.8M COOL.CXCore One Labs, Inc.-- -- -- -
What do Analysts Say About LOVE.V or COOL.CX?
Cannara Biotech, Inc. has a consensus price target of $3.50, signalling upside risk potential of 107.1%. On the other hand Core One Labs, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Cannara Biotech, Inc. has higher upside potential than Core One Labs, Inc., analysts believe Cannara Biotech, Inc. is more attractive than Core One Labs, Inc..
Company Buy Ratings Hold Ratings Sell Ratings LOVE.VCannara Biotech, Inc.1 0 0 COOL.CXCore One Labs, Inc.0 0 0 -
Is LOVE.V or COOL.CX More Risky?
Cannara Biotech, Inc. has a beta of 0.326, which suggesting that the stock is 67.383% less volatile than S&P 500. In comparison Core One Labs, Inc. has a beta of 0.495, suggesting its less volatile than the S&P 500 by 50.458%.
-
Which is a Better Dividend Stock LOVE.V or COOL.CX?
Cannara Biotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Core One Labs, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cannara Biotech, Inc. pays -- of its earnings as a dividend. Core One Labs, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LOVE.V or COOL.CX?
Cannara Biotech, Inc. quarterly revenues are $28.3M, which are larger than Core One Labs, Inc. quarterly revenues of --. Cannara Biotech, Inc.'s net income of $3.3M is higher than Core One Labs, Inc.'s net income of --. Notably, Cannara Biotech, Inc.'s price-to-earnings ratio is 11.90x while Core One Labs, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cannara Biotech, Inc. is 1.45x versus 32.71x for Core One Labs, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LOVE.VCannara Biotech, Inc.1.45x 11.90x $28.3M $3.3M COOL.CXCore One Labs, Inc.32.71x -- -- --
-
Which has Higher Returns LOVE.V or CURE.X.CX?
Biocure Technology has a net margin of 11.7% compared to Cannara Biotech, Inc.'s net margin of --. Cannara Biotech, Inc.'s return on equity of 13.81% beat Biocure Technology's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital LOVE.VCannara Biotech, Inc.12.11% $0.04 $143.8M CURE.X.CXBiocure Technology-- -- -- -
What do Analysts Say About LOVE.V or CURE.X.CX?
Cannara Biotech, Inc. has a consensus price target of $3.50, signalling upside risk potential of 107.1%. On the other hand Biocure Technology has an analysts' consensus of -- which suggests that it could fall by --. Given that Cannara Biotech, Inc. has higher upside potential than Biocure Technology, analysts believe Cannara Biotech, Inc. is more attractive than Biocure Technology.
Company Buy Ratings Hold Ratings Sell Ratings LOVE.VCannara Biotech, Inc.1 0 0 CURE.X.CXBiocure Technology0 0 0 -
Is LOVE.V or CURE.X.CX More Risky?
Cannara Biotech, Inc. has a beta of 0.326, which suggesting that the stock is 67.383% less volatile than S&P 500. In comparison Biocure Technology has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock LOVE.V or CURE.X.CX?
Cannara Biotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biocure Technology offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cannara Biotech, Inc. pays -- of its earnings as a dividend. Biocure Technology pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LOVE.V or CURE.X.CX?
Cannara Biotech, Inc. quarterly revenues are $28.3M, which are larger than Biocure Technology quarterly revenues of --. Cannara Biotech, Inc.'s net income of $3.3M is higher than Biocure Technology's net income of --. Notably, Cannara Biotech, Inc.'s price-to-earnings ratio is 11.90x while Biocure Technology's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cannara Biotech, Inc. is 1.45x versus -- for Biocure Technology. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LOVE.VCannara Biotech, Inc.1.45x 11.90x $28.3M $3.3M CURE.X.CXBiocure Technology-- -- -- --
-
Which has Higher Returns LOVE.V or HEAL.CX?
has a net margin of 11.7% compared to Cannara Biotech, Inc.'s net margin of --. Cannara Biotech, Inc.'s return on equity of 13.81% beat 's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital LOVE.VCannara Biotech, Inc.12.11% $0.04 $143.8M HEAL.CX-- -- -- -
What do Analysts Say About LOVE.V or HEAL.CX?
Cannara Biotech, Inc. has a consensus price target of $3.50, signalling upside risk potential of 107.1%. On the other hand has an analysts' consensus of -- which suggests that it could fall by --. Given that Cannara Biotech, Inc. has higher upside potential than , analysts believe Cannara Biotech, Inc. is more attractive than .
Company Buy Ratings Hold Ratings Sell Ratings LOVE.VCannara Biotech, Inc.1 0 0 HEAL.CX0 0 0 -
Is LOVE.V or HEAL.CX More Risky?
Cannara Biotech, Inc. has a beta of 0.326, which suggesting that the stock is 67.383% less volatile than S&P 500. In comparison has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock LOVE.V or HEAL.CX?
Cannara Biotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cannara Biotech, Inc. pays -- of its earnings as a dividend. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LOVE.V or HEAL.CX?
Cannara Biotech, Inc. quarterly revenues are $28.3M, which are larger than quarterly revenues of --. Cannara Biotech, Inc.'s net income of $3.3M is higher than 's net income of --. Notably, Cannara Biotech, Inc.'s price-to-earnings ratio is 11.90x while 's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cannara Biotech, Inc. is 1.45x versus -- for . Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LOVE.VCannara Biotech, Inc.1.45x 11.90x $28.3M $3.3M HEAL.CX-- -- -- --
-
Which has Higher Returns LOVE.V or NSHS.CX?
NanoSphere Health Sciences, Inc. has a net margin of 11.7% compared to Cannara Biotech, Inc.'s net margin of --. Cannara Biotech, Inc.'s return on equity of 13.81% beat NanoSphere Health Sciences, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital LOVE.VCannara Biotech, Inc.12.11% $0.04 $143.8M NSHS.CXNanoSphere Health Sciences, Inc.-- -$0.00 -$1.8M -
What do Analysts Say About LOVE.V or NSHS.CX?
Cannara Biotech, Inc. has a consensus price target of $3.50, signalling upside risk potential of 107.1%. On the other hand NanoSphere Health Sciences, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Cannara Biotech, Inc. has higher upside potential than NanoSphere Health Sciences, Inc., analysts believe Cannara Biotech, Inc. is more attractive than NanoSphere Health Sciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings LOVE.VCannara Biotech, Inc.1 0 0 NSHS.CXNanoSphere Health Sciences, Inc.0 0 0 -
Is LOVE.V or NSHS.CX More Risky?
Cannara Biotech, Inc. has a beta of 0.326, which suggesting that the stock is 67.383% less volatile than S&P 500. In comparison NanoSphere Health Sciences, Inc. has a beta of 0.627, suggesting its less volatile than the S&P 500 by 37.292%.
-
Which is a Better Dividend Stock LOVE.V or NSHS.CX?
Cannara Biotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NanoSphere Health Sciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cannara Biotech, Inc. pays -- of its earnings as a dividend. NanoSphere Health Sciences, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LOVE.V or NSHS.CX?
Cannara Biotech, Inc. quarterly revenues are $28.3M, which are larger than NanoSphere Health Sciences, Inc. quarterly revenues of --. Cannara Biotech, Inc.'s net income of $3.3M is higher than NanoSphere Health Sciences, Inc.'s net income of -$13.1K. Notably, Cannara Biotech, Inc.'s price-to-earnings ratio is 11.90x while NanoSphere Health Sciences, Inc.'s PE ratio is 0.52x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cannara Biotech, Inc. is 1.45x versus -- for NanoSphere Health Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LOVE.VCannara Biotech, Inc.1.45x 11.90x $28.3M $3.3M NSHS.CXNanoSphere Health Sciences, Inc.-- 0.52x -- -$13.1K
-
Which has Higher Returns LOVE.V or XLY.TO?
Auxly Cannabis Group, Inc. has a net margin of 11.7% compared to Cannara Biotech, Inc.'s net margin of 51.36%. Cannara Biotech, Inc.'s return on equity of 13.81% beat Auxly Cannabis Group, Inc.'s return on equity of 34.07%.
Company Gross Margin Earnings Per Share Invested Capital LOVE.VCannara Biotech, Inc.12.11% $0.04 $143.8M XLY.TOAuxly Cannabis Group, Inc.22.15% $0.01 $238.5M -
What do Analysts Say About LOVE.V or XLY.TO?
Cannara Biotech, Inc. has a consensus price target of $3.50, signalling upside risk potential of 107.1%. On the other hand Auxly Cannabis Group, Inc. has an analysts' consensus of $0.2500 which suggests that it could grow by 78.57%. Given that Cannara Biotech, Inc. has higher upside potential than Auxly Cannabis Group, Inc., analysts believe Cannara Biotech, Inc. is more attractive than Auxly Cannabis Group, Inc..
Company Buy Ratings Hold Ratings Sell Ratings LOVE.VCannara Biotech, Inc.1 0 0 XLY.TOAuxly Cannabis Group, Inc.1 0 0 -
Is LOVE.V or XLY.TO More Risky?
Cannara Biotech, Inc. has a beta of 0.326, which suggesting that the stock is 67.383% less volatile than S&P 500. In comparison Auxly Cannabis Group, Inc. has a beta of 1.254, suggesting its more volatile than the S&P 500 by 25.413%.
-
Which is a Better Dividend Stock LOVE.V or XLY.TO?
Cannara Biotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Auxly Cannabis Group, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cannara Biotech, Inc. pays -- of its earnings as a dividend. Auxly Cannabis Group, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LOVE.V or XLY.TO?
Cannara Biotech, Inc. quarterly revenues are $28.3M, which are smaller than Auxly Cannabis Group, Inc. quarterly revenues of $39.9M. Cannara Biotech, Inc.'s net income of $3.3M is lower than Auxly Cannabis Group, Inc.'s net income of $20.5M. Notably, Cannara Biotech, Inc.'s price-to-earnings ratio is 11.90x while Auxly Cannabis Group, Inc.'s PE ratio is 4.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cannara Biotech, Inc. is 1.45x versus 1.40x for Auxly Cannabis Group, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LOVE.VCannara Biotech, Inc.1.45x 11.90x $28.3M $3.3M XLY.TOAuxly Cannabis Group, Inc.1.40x 4.59x $39.9M $20.5M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Sell
14
SMX alert for Dec 30
SMX (Security Matters) Plc [SMX] is down 40.26% over the past day.
Buy
71
ZCSH alert for Dec 30
Grayscale Zcash Trust (ZEC) [ZCSH] is down 4.56% over the past day.
Buy
69
GDXU alert for Dec 30
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is up 3.19% over the past day.
